AMAndrew M. Miller

Andrew M. Miller

*This is an algorithmically generated author record based on publicly available information.

Andrew M. Miller has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Complications Associated With Removal of Paddle and Cylindrical Spinal Cord Stimulator Electrodes

    by Andrew M. Miller, Alan Bs Nguyen, Adeesya Ba Gausper, Corey T. Walker, Tiffany G. Perry, Alexander Tuchman

    Study Design: Retrospective case series. Objective: We aim to examine complications associated with the removal of spinal cord stimulator electrodes for the first time in a large cohort of patients that included both paddle and cylindrical electrodes. Summary of Background Data: Spinal cord stimulation (SCS) is a reversible treatment for many chronic pain syndromes that involves either open surgical placement of paddle electrodes or percutaneous placement of cylindrical leads. Potential complications associated with SCS removal are not well described in the literature. Methods: We conducted a retrospective chart review of 139 patients who underwent removal of spinal cord stimulator electrodes at our institution between 2014 and 2022. Results: Nine out of 139 patients (6.5%) experienced postoperative complications, 7 of which occurred in patients who underwent more extensive concurrent spine surgeries. A complication occurred in only two of the 82 patients (2.4%) who had removal of their electrodes as a standalone procedure. In all but one patient (0.7%), the electrodes were able to be removed in their entirety. Conclusions: Surgical removal of both cylindrical and paddle SCS electrodes as a standalone procedure is associated with a low rate of complications. Most observed complications occurred in patients who underwent concurrent spinal surgery and were likely attributable to those additional procedures rather than electrode removal itself.


  • Washout of chronic therapeutic deep brain stimulation increases cortical phase-amplitude coupling

    by Sheila S. Rajagopalan, Andrew M. Miller, Coralie de Hemptinne, Marta San Luciano, Jill L. Ostrem, Philip A. Starr


  • Effect of levodopa on electroencephalographic biomarkers of the parkinsonian state

    by Andrew M. Miller, Svjetlana Miocinovic, Nicole C. Swann, Sheila S. Rajagopalan, David M. Darevsky, Ro’eE Gilron, Coralie de Hemptinne, Jill L. Ostrem, Philip A. Starr

    The objective of this study was to evaluate proposed electroencephalographic (EEG) biomarkers of Parkinson’s disease (PD) and test their correlation with motor impairment in a new, well-characterized cohort of PD patients and controls. Sixty-four-channel EEG was recorded from 14 patients with rigid-akinetic PD with minimal tremor and from 14 age-matched healthy controls at rest and during voluntary movement. Patients were tested off and on medication during a single session. Recordings were analyzed for phase-amplitude coupling over sensorimotor cortex and for pairwise coherence from all electrode pairs in the recording montage (distributed coherence). Phase-amplitude coupling and distributed coherence were found to be elevated Off compared with On levodopa, and their reduction was correlated with motor improvement. In the Off medication state, phase-amplitude coupling was greater in sensorimotor contacts contralateral to the most affected body part and reduced by voluntary movement. We conclude that phase-amplitude coupling and distributed coherence are cortical biomarkers of the parkinsonian state that are detectable noninvasively and may be useful as objective aids for management of dopaminergic therapy. Several analytic methods may be used for noninvasive measurement of abnormal brain synchronization in PD. Calculation of phase-amplitude coupling requires only a single electrode over motor cortex. NEW & NOTEWORTHY Several EEG biomarkers of the parkinsonian state have been proposed that are related to abnormal cortical synchronization. We report several new findings in this study: correlations of EEG markers of synchronization with specific motor signs of Parkinson’s disease (PD), and demonstration that one of the EEG markers, phase-amplitude coupling, is more elevated over the more clinically affected brain hemisphere. These findings underscore the potential utility of scalp EEG for objective, noninvasive monitoring of medication state in PD.


  • Open Access

    Constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1) is associated with skeletal muscle insulin resistance

    by Thomas Henry Reynolds, Charlie Phelps, Eli Berk, Andrew Miller

    The present study assessed mTORC1 activity in isolated rat skeletal muscles and in skeletal muscles of Ob/Ob (OB) mice. Epitrochlearis muscles isolated from rats were incubated with insulin (750 uU/ml) and/or amino acids (2.5X MEM). Amino acids produced a significant reduction in the ability of insulin to promote protein kinase B (PKB) phosphorylation, a process that was reversed by rapamycin (100nM). Amino acids did not inhibit the ability of insulin to promote the phosphorylation of PRAS40 on Thr‐246, a site whose phosphorylation enhances mTORC1 activity. In vivo insulin action was assessed in muscles of OB and wild type (WT) mice by intraperitoneal injections of insulin (0.25 U/Kg) or saline. In the basal state, phosphorylation of S6K on Thr‐389 and PRAS40 on Thr‐246 were increased significantly in muscles of OB compared to WT mice. In the insulin‐stimulated state, phosphorylation of S6K on Thr‐389 and PRAS40 on Thr‐246 were similar in muscles of OB compared to WT mice. We also assessed whether or not 5 days of rapamycin treatment (0.75 mg/Kg/day) could improve the insulin resistance of OB mice. Rapamycin treatment exacerbated the insulin resistance of Ob mice, indicating that some mTORC1 activity is necessary for normal in vivo glucose disposal. These results indicate that mTORC1 signaling is associated with insulin resistance, but inhibiting mTORC1 activity with rapamycin does not improve in vivo insulin action.